Altrinsic Global Advisors’s Xenon Pharmaceuticals XENE Stock Holding History

Altrinsic Global Advisors’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-170,000	Closed	-$5.31M	–	71
2021 Q4	$5.31M	Hold	170,000	–	–	0.17%	47
2021 Q3	$2.6M	Hold	170,000	–	–	0.08%	60
2021 Q2	$3.17M	Hold	170,000	–	–	0.1%	56
2021 Q1	$3.04M	Hold	170,000	–	–	0.1%	56
2020 Q4	$2.62M	Hold	170,000	–	–	0.09%	53
2020 Q3	$1.88M	Hold	170,000	–	–	0.08%	55
2020 Q2	$2.13M	Hold	170,000	–	–	0.09%	54
2020 Q1	$1.93M	Sell	170,000 -10,000	-6%	-$142K	0.11%	51
2019 Q4	$2.36M	Hold	180,000	–	–	0.1%	51
2019 Q3	$1.62M	Hold	180,000	–	–	0.07%	57
2019 Q2	$1.77M	Buy	180,000 +20,000	+13%	+$191K	0.08%	59
2019 Q1	$1.63M	Buy	160,000 +10,000	+7%	+$84.8K	0.08%	64
2018 Q4	$947K	Buy	150,000 +30,000	+25%	+$267K	0.05%	67
2018 Q3	$1.58M	Buy	+120,000	New	+$1.39M	0.07%	67

Other funds holding XENE

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Altrinsic Global Advisors's XENE Position: Q1 2022 in Review

Altrinsic Global Advisors sold out of Xenon Pharmaceuticals (XENE) in Q1 2022, closing a stake of 170,000 shares — an estimated $5.31M sold.

Altrinsic Global Advisors first reported a position in XENE in Q3 2018 and held it in 14 quarters. The position peaked at $5.31M in Q4 2021. 133 funds tracked by Wall St. Rank hold XENE as of Q1 2022.

Altrinsic Global Advisors reported no remaining Xenon Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Altrinsic Global Advisors sold 170,000 Xenon Pharmaceuticals shares in Q1 2022, an estimated $5.31M.
Altrinsic Global Advisors first reported a position in Xenon Pharmaceuticals in Q3 2018 and held it in 14 quarters.
Altrinsic Global Advisors's Xenon Pharmaceuticals position peaked at $5.31M in Q4 2021.
133 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2022.

Based on Altrinsic Global Advisors's 13F filing for Q1 2022, filed 16 May 2022.